8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Apr 13, 2026·SEC
Material company update
Mar 17, 2026·SEC
ImageneBio Inc(IMA)Earnings, Financials & Key Ratios
IMA•NASDAQ
$6.00
Price updated Jul 6, 2026
AboutClinical-stage biotechnology company developing differentiated therapies for immunological/autoimmune & inflammatory (I&I) diseases, notably non‑depleting anti‑OX40 monoclonal antibody IMG‑007 in Phase 2b for atopic dermatitisShow more
- Revenue$800K-77.1%
- EBITDA-$47M-33.7%
- Net Income-$45M-24.0%
- EPS (Diluted)-10.76-954.9%
- Gross Margin-29.13%-129.1%
- EBITDA Margin-5927.25%-484.8%
- Operating Margin-6056.38%-472.9%
- Net Margin-5668.63%-442.6%
- ROE-35.01%-41.5%
IMA Price & Volume
ImageneBio Inc (IMA) stock price & volume — 10-year historical chart
Loading chart...
Persistent Revenue Absence Drives Structural Capital Erosion
Investment Thesis • Updated 2026Q1
VerdictNegative: The company exhibits a persistent and unmitigated cash burn rate
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Total Capital Erosion
Key Thesis Takeaways
- ImageneBio faces a precarious outlook characterized by a complete cessation of revenue since 2024Q1 and a persistent quarterly cash burn that reached $14.8 million in 2026Q1.
- The company's reliance on external capital to fund R&D initiatives, which totaled $6.0 million in the most recent quarter, underscores a high-risk profile with no clear path to commercial viability.
- Investors should monitor the rapid depletion of the asset base, which has contracted from $192.1 million in 2023Q4 to $136.7 million as of 2026Q1, as the firm continues to accumulate significant deficits.
Verdict Logic
evidenced by a $14.8 million negative free cash flow in 2026Q1 and a total absence of revenue generation.
IMA Growth Metrics
ImageneBio Inc (IMA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-38.64%
3 Years-62.86%
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-8.07%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-439.22%
Return on Capital
10 Years-62.05%
5 Years-32.51%
3 Years-35.15%
Last Year-35.56%
Peers Comparison
Key metrics vs top competitors for ImageneBio Inc (IMA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $6.00 | $67.67M | -0.56 | -77.14% | -5668.63% | -35.01% | — | |
| $23.66 | $176.92M | -0.73 | -67.37% | -4571.14% | — | — | |
| $38.60 | $7.92B | -13.94 | — | — | -68.16% | — | |
| $114.76 | $9.37B | -31.10 | -16.72% | -612.17% | -25.02% | — | |
| $26.07 | $3.26B | -200.54 | 91.34% | -0.57% | -1.41% | — | |
| $9.50 | $497.36M | -2.10 | -92.84% | -260.92% | -49.88% | — |
Compare IMA vs Peers
ImageneBio Inc (IMA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
IMA SEC Filings & Documents
ImageneBio Inc (IMA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when IMA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
IMA Frequently Asked Questions
ImageneBio Inc (IMA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is ImageneBio Inc's revenue?
ImageneBio Inc (IMA) reported $0.8M in revenue for fiscal year 2025. This represents a 19% decrease from $1.0M in 2018.
How fast is ImageneBio Inc growing?
ImageneBio Inc (IMA) saw revenue decline by 77.1% over the past year.
Is IMA profitable?
ImageneBio Inc (IMA) reported a net loss of $45.1M for fiscal year 2025.
Dividend & Returns
What is IMA's return on equity?
ImageneBio Inc (IMA) has a return on equity (ROE) of -35.0%. Negative ROE indicates the company is unprofitable.
What is ImageneBio Inc's free cash flow?
ImageneBio Inc (IMA) had negative free cash flow of $52.1M in fiscal year 2025, likely due to heavy capital investments.